Reuters logo
5 months ago
BRIEF-FDA accepts supplemental new drug application (SNDA) for vraylar
March 8, 2017 / 2:16 PM / 5 months ago

BRIEF-FDA accepts supplemental new drug application (SNDA) for vraylar

March 8 (Reuters) - Allergan Plc

* FDA accepts supplemental new drug application (SNDA) for vraylar (cariprazine)

* Application seeks to expand vraylar label to include Phase 3 clinical data for maintenance treatment of schizophrenia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below